<DOC>
	<DOC>NCT01409070</DOC>
	<brief_summary>In Myelodysplastic syndrome, epigenetic treatments such as Azacitidine and Decitabine have been highlighted in phase 3 studies. However, as the 1st line treatment, it has not been evaluated the head to head comparison of two drugs. This study is a retrospective study to compare the efficacy of two drugs.</brief_summary>
	<brief_title>Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome</brief_title>
	<detailed_description>Among 300 MDS patient, 200 of them have been taking Azacitidine and 100 of them have been taking Decitabine. Medical chart of these patients will be reviewed to assess the efficacy and safety between two agents.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Confirmed MDS by bone marrow examination Receiving azacitidine and decitabine as a first line chemotherapy Adequate hepatic, cardiac, and renal function Previously treated with another anticancer therapy due to MDS Not available for clinical information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>MDS</keyword>
</DOC>